274 related articles for article (PubMed ID: 33984191)
1. Does atorvastatin therapy change the anti-Xa activity in xabans-treated patients with atrial fibrillation?
Škorňová I; Samoš M; Bolek T; Stančiaková L; Vádelová Ľ; Galajda P; Staško J; Kubisz P; Mokáň M
Pharmacol Res Perspect; 2021 May; 9(3):e00730. PubMed ID: 33984191
[TBL] [Abstract][Full Text] [Related]
2. Does proton pump inhibition change the on-treatment anti-Xa activity in xabans-treated patients with atrial fibrillation? A pilot study.
Bolek T; Samoš M; Škorňová I; Stančiaková L; Staško J; Korpallová B; Galajda P; Kubisz P; Mokáň M
J Thromb Thrombolysis; 2019 Jan; 47(1):140-145. PubMed ID: 30288664
[TBL] [Abstract][Full Text] [Related]
3. Anti-Xa activity in oral factor Xa inhibitor-treated patients with atrial fibrillation and a higher risk of bleeding: a pilot study.
Samoš M; Bolek T; Stančiaková L; Škorňová I; Bánovčin P; Kovář F; Staško J; Galajda P; Kubisz P; Mokáň M
Blood Coagul Fibrinolysis; 2018 Jun; 29(4):369-373. PubMed ID: 29538002
[TBL] [Abstract][Full Text] [Related]
4. Comparison of Anti-factor Xa Activity Among Three Different Factor Xa Inhibitors in Non-valvular Atrial Fibrillation Patients with Renal Impairment.
Tobe A; Osanai H; Tanaka A; Sakaguchi T; Kambara T; Nakashima Y; Asano H; Ishii H; Ajioka M; Murohara T
Clin Drug Investig; 2020 Jun; 40(6):567-573. PubMed ID: 32314297
[TBL] [Abstract][Full Text] [Related]
5. Plasma levels of direct oral anticoagulants in atrial fibrillation patients at the time of embolic stroke: a pilot prospective multicenter study.
Nosáľ V; Petrovičová A; Škorňová I; Bolek T; Dluhá J; Stančiaková L; Sivák Š; Babálová L; Hajaš G; Staško J; Kubisz P; Kurča E; Samoš M; Mokáň M
Eur J Clin Pharmacol; 2022 Apr; 78(4):557-564. PubMed ID: 35066599
[TBL] [Abstract][Full Text] [Related]
6. Direct Oral Anticoagulants Plasma Levels in Patients with Atrial Fibrillation at the Time of Bleeding: A Pilot Prospective Study.
Škorňová I; Samoš M; Bolek T; Kamenišťáková A; Stančiaková L; Galajda P; Staško J; Kubisz P; Mokáň M
J Cardiovasc Pharmacol; 2021 Jul; 78(1):e122-e127. PubMed ID: 34173805
[TBL] [Abstract][Full Text] [Related]
7. Assessment of Anti-Xa activity in patients receiving concomitant apixaban with strong p-glycoprotein inhibitors and statins.
Milner E; Ainsworth M; Gleaton M; Bookstaver D
J Clin Pharm Ther; 2022 May; 47(5):668-675. PubMed ID: 35032137
[TBL] [Abstract][Full Text] [Related]
8. Lupus anticoagulant diagnosis in patients receiving direct oral FXa inhibitors at trough levels: A real-life study.
Gay J; Duchemin J; Imarazene M; Fontenay M; Jourdi G
Int J Lab Hematol; 2019 Dec; 41(6):738-744. PubMed ID: 31487115
[TBL] [Abstract][Full Text] [Related]
9. Anti-Xa Oral Anticoagulant Plasma Concentration Assay in Real Life: Rivaroxaban and Apixaban Quantification in Emergency With LMWH Calibrator.
Billoir P; Barbay V; Joly LM; Fresel M; Chrétien MH; Le Cam Duchez V
Ann Pharmacother; 2019 Apr; 53(4):341-347. PubMed ID: 30378443
[TBL] [Abstract][Full Text] [Related]
10. Direct Comparison of Dabigatran, Rivaroxaban, and Apixaban for Effectiveness and Safety in Nonvalvular Atrial Fibrillation.
Noseworthy PA; Yao X; Abraham NS; Sangaralingham LR; McBane RD; Shah ND
Chest; 2016 Dec; 150(6):1302-1312. PubMed ID: 27938741
[TBL] [Abstract][Full Text] [Related]
11. Anti-Xa Monitoring of Apixaban (ZyQuis) in Venous Thrombo-Embolism and Atrial Fibrillation.
Schapkaitz E; Ter Morshuizen B; Mc Cree M; F Jacobson B
Clin Appl Thromb Hemost; 2024; 30():10760296241249167. PubMed ID: 38659339
[TBL] [Abstract][Full Text] [Related]
12. Evaluation of global laboratory methods and establishing on-therapy ranges for monitoring apixaban and rivaroxaban: Experience at a single institution.
Park SH; Seo YH; Park PW; Kim KH; Seo JY; Lee HT; Kwoun WJ; Ahn JY
J Clin Lab Anal; 2019 Jun; 33(5):e22869. PubMed ID: 30860622
[TBL] [Abstract][Full Text] [Related]
13. Effectiveness and Safety of Apixaban Versus Rivaroxaban for Patients With Atrial Fibrillation.
Ann Intern Med; 2020 Apr; 172(7):. PubMed ID: 32150747
[No Abstract] [Full Text] [Related]
14. Incremental economic burden associated with major bleeding among atrial fibrillation patients treated with factor Xa inhibitors.
Deitelzweig S; Neuman WR; Lingohr-Smith M; Menges B; Lin J
J Med Econ; 2017 Dec; 20(12):1217-1223. PubMed ID: 28760063
[TBL] [Abstract][Full Text] [Related]
15. Effect of the FXa inhibitors Rivaroxaban and Apixaban on platelet activation in patients with atrial fibrillation.
Steppich B; Dobler F; Brendel LC; Hessling G; Braun SL; Steinsiek AL; Deisenhofer I; Hyseni A; Roest M; Ott I
J Thromb Thrombolysis; 2017 May; 43(4):490-497. PubMed ID: 28316004
[TBL] [Abstract][Full Text] [Related]
16. Monitoring the roles of prothrombin activation fragment 1 and 2 (F1 + 2) in patients with atrial fibrillation receiving rivaroxaban and apixaban.
Ueno EI; Fujibayashi K; Sawaguchi J; Yasuda Y; Takano S; Fujioka N; Kawai Y; Fujita H; Tanaka Y; Kajinami K
J Thromb Thrombolysis; 2020 Aug; 50(2):371-379. PubMed ID: 32166540
[TBL] [Abstract][Full Text] [Related]
17. Comparative effectiveness and safety of apixaban, dabigatran, and rivaroxaban in patients with non-valvular atrial fibrillation.
Andersson NW; Svanström H; Lund M; Pasternak B; Melbye M
Int J Cardiol; 2018 Oct; 268():113-119. PubMed ID: 29934230
[TBL] [Abstract][Full Text] [Related]
18. Direct comparative effectiveness and safety between non-vitamin K antagonist oral anticoagulants for stroke prevention in nonvalvular atrial fibrillation: a systematic review and meta-analysis of observational studies.
Li G; Lip GYH; Holbrook A; Chang Y; Larsen TB; Sun X; Tang J; Mbuagbaw L; Witt DM; Crowther M; Thabane L; Levine MAH
Eur J Epidemiol; 2019 Feb; 34(2):173-190. PubMed ID: 29948370
[TBL] [Abstract][Full Text] [Related]
19. Network Meta-Analysis Comparing Apixaban Versus Rivaroxaban in Morbidly Obese Patients With Atrial Fibrillation.
Kido K; Shimizu M; Shiga T; Hashiguchi M
Am J Cardiol; 2020 Nov; 134():160-161. PubMed ID: 32916147
[No Abstract] [Full Text] [Related]
20. Intra- and inter- individual rivaroxaban concentrations and potential bleeding risk in patients with atrial fibrillation.
Miklič M; Mavri A; Vene N; Söderblom L; Božič-Mijovski M; Pohanka A; Antovic J; Malmström RE
Eur J Clin Pharmacol; 2019 Aug; 75(8):1069-1075. PubMed ID: 31139866
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
